This monthly feature will help readers keep current on new drugs, new indications, dosage forms, and safety-related changes in labeling or use. Efforts have been made to ensure the accuracy of this information; however, if there are any questions, please let me know at danial.baker@wsu.edu.
WARNINGS AND PRECAUTIONS Vulnerability to Opioid Overdose: Patients should be alerted that they may be more sensitive to opioids, even at lower doses, after naltrexone treatment is discontinued, especially at the end of a dosing interval (ie, near the end of the month that Vivitrol was administered), or after a dose of Vivitrol is missed. It is important that patients inform family members and the people closest to the patient of this increased sensitivity to opioids and the risk of overdose. Injection Site Reactions: For patients with a larger amount of subcutaneous tissue overlying the gluteal muscle, the administering health care provider may utilize the supplied 2-inch needle with needle protection device to help ensure that the injectate reaches the intramuscular mass. For very lean patients, the 1.5-inch needle may be appropriate to prevent the needle contacting the periosteum. Either needle may be used for patients with average body habitus. Precipitation of Opioid Withdrawal: The symptoms of spontaneous opioid withdrawal (which are associated with the discontinuation of opioid in a dependent individual) are uncomfortable, but they are not generally believed to be severe or necessitate hospitalization. However, when withdrawal is precipitated abruptly by the administration of an opioid antagonist to an opioid-dependent patient, the resulting withdrawal syndrome can be severe enough to require hospitalization. Review of postmarketing cases of precipitated opioid withdrawal in association with naltrexone treatment has identified cases with symptoms of withdrawal severe enough to require hospital admission and, in some cases, management in the intensive care unit. Hepatotoxicity: Cases of hepatitis and clinically significant liver dysfunction were observed in association with Vivitrol exposure during the clinical development program and in the postmarketing period.
http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm208449.htm 
CONTRAINDICATIONS
Patients with significant respiratory depression; acute or severe bronchial asthma or hypercarbia in an unmonitored setting or in the absence of resuscitative equipment; known or suspected paralytic ileus; or hypersensitivity (eg, anaphylaxis, angioedema) to tapentadol or to any other ingredients of the product WARNINGS AND PRECAUTIONS Abuse Potential: Tapentadol, an opioid agonist and a Schedule II controlled substance, can be abused in a manner similar to other opioid agonists legal or illicit. Consider these risks when prescribing or dispensing in situations where there is concern about increased risks of misuse, abuse, or diversion. 
THERAPY CONSIDERATIONS
Metformin alone or in combination with lifestyle modification in the treatment and prevention of antipsychotic weight gain has been studied in several meta-analyses and controlled trials, suggesting a modest weight loss in most patients (2.93 to 5 kg).
